Guardant Health announced that its blood-based colorectal cancer screening test Shield is now accessible nationwide through the testing network of Quest Diagnostics.
The partnership allows physicians to order Shield through existing Quest accounts and EHR systems, while patients can access testing through Quest’s ~2,000 patient service centers and 6,000 phlebotomists. Shield is the first blood test fully approved by the FDA as a primary colorectal cancer screening option for average-risk adults aged 45+.
The company reports that the test has shown 93% screening adherence in real-world use, offering a potentially easier alternative to colonoscopy or stool-based screening and aiming to increase CRC screening participation.